An EMA survey has found that 42% of businesses, with an important step in their regulatory processes occurring in the UK, are not adequately prepared to retain marketing authorisation post-Brexit.
Forbion looks to take advantage of 'undersupply' of capital to European life sciences
from BioPharma-Reporter.com
Clinical technology is broken, so what is being done to fix it?
from Outsourcing-Pharma.com
Pluristem brings in Thermo Fisher to ‘transform cell therapy manufacturing’
from BioPharma-Reporter.com
Warning, recall, alert: Unsanitary lab conditions raise US FDA alarm
from Outsourcing-Pharma.com
Recipharm anticipates FMD compliance struggles, launches standalone service
Globalisation
Bain Capital buys DSM Sinochem Pharmaceuticals, ‘fully supports’ API biz
Mergers and acquisitions
Tracelink partners with IBI Lorenzini, as FMD deadline looms over Europe
Globalisation
AbbVie hit with record $448m US FTC antitrust fine
Lifecycle management
